Metronomic chemotherapy with capecitabine for metastatic colorectal cancer in very elderly patients
Yun Hwa Jung, Won Jik Lee, Jae Ho Byeon, In Kyu Lee, Chi Wha Han, In Sook Woo
Korean J Intern Med. 2017;32(5):926-929. Published online 2016 Mar 10 DOI: https://doi.org/10.3904/kjim.2015.049
Citations to this article as recorded by 
First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer
Arthur Winer, Crystal S. Denlinger, Namrata Vijayvergia, Steven J. Cohen, Igor Astaturov, Efrat Dotan, Jean-Nicolas Gallant, Edward W. Wang, Miriam Kunkel, Bora Lim, Harold A. Harvey, Jeffrey Sivik, Kenneth Korzekwa, Karen Ruth, Kevin White, Harry S. Coop
Clinical Colorectal Cancer.2021; 20(1): e43. CrossRef
Antibody–drug conjugates, cancer immunotherapy, and metronomic chemotherapy as novel approaches in cancer management
SudhirChandra Sarangi, Pranav Sopory, SoumyaSucharita Pattnaik, KH Reeta
Indian Journal of Pharmacology.2020; 52(5): 402. CrossRef
Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients
Rui Geng, Gang Wang, Lei Qiu, Bing Liu, Fan Yang, Jingyu Zhang, Yongchang Miao
Medicine.2020; 99(51): e23719. CrossRef
Clinical characteristics and treatment propensity in elderly patients aged over 80 years with colorectal cancer
Yun Hwa Jung, Jae Young Kim, Yu Na Jang, Sang Hoon Yoo, Gyo Hui Kim, Kang Min Lee, In Kyu Lee, Su Mi Chung, In Sook Woo
The Korean Journal of Internal Medicine.2018; 33(6): 1182. CrossRef